Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Immutep aggregated by PharmaCompass.com.

    Client Virtual Booth

    IMMUTEP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Immutep
    Australia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 12, 95 Pitt Street Sydney, NSW 2000
    Telephone
    Telephone
    +61 2 9290 9600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immutep.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/857541/
    Twitter
    Twitter
    https://twitter.com/immutep?lang=en/

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Immutep Announces First Clinical Data from 90mg Dosing of Efti
    Immutep Announces First Clinical Data from 90mg Dosing of Efti

    https://www.globenewswire.com//news-release/2024/03/05/2840402/0/en/Immutep-Announces-First-Clinical-Data-from-90mg-Dosing-of-Efti.html

    GLOBENEWSWIRE
    05 Mar 2024
    Share Share
    Immutep Quarterly Activities Report Q2 FY24
    Immutep Quarterly Activities Report Q2 FY24

    https://www.globenewswire.com/news-release/2024/01/30/2819933/0/en/Immutep-Quarterly-Activities-Report-Q2-FY24.html

    GLOBENEWSWIRE
    30 Jan 2024
    Share Share
    Immutep Receives Constructive Regulatory Feedback on TACTI-004 Trial
    Immutep Receives Constructive Regulatory Feedback on TACTI-004 Trial

    https://www.globenewswire.com//news-release/2023/12/21/2799956/0/en/Immutep-Receives-Constructive-Regulatory-Feedback-on-TACTI-004-Registrational-Trial-in-Metastatic-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    21 Dec 2023
    Share Share
    Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
    Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

    https://www.globenewswire.com//news-release/2023/11/22/2784753/0/en/Immutep-Announces-Site-Expansion-for-INSIGHT-003-Phase-I-Trial.html

    GLOBENEWSWIRE
    22 Nov 2023
    Share Share
    Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA
    Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA

    https://www.globenewswire.com//news-release/2023/11/09/2777267/0/en/Immutep-Completes-Enrollment-in-TACTI-003-Phase-IIb-Trial-of-Efti-and-KEYTRUDA-in-First-Line-Metastatic-or-Recurrent-Head-and-Neck-Squamous-Cell-Carcinoma.html

    GLOBENEWSWIRE
    09 Nov 2023
    Share Share
    Immutep Announces New Biomarker Data from TACTI-002 Phase II
    Immutep Announces New Biomarker Data from TACTI-002 Phase II

    https://www.globenewswire.com//news-release/2023/11/03/2773320/0/en/Immutep-Announces-New-Biomarker-Data-from-TACTI-002-Phase-II-in-First-Line-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    03 Nov 2023
    Share Share
    Immutep to Participate in November Investor Events
    Immutep to Participate in November Investor Events

    https://www.globenewswire.com//news-release/2023/11/02/2772258/0/en/Immutep-to-Participate-in-November-Investor-Events.html

    GLOBENEWSWIRE
    02 Nov 2023
    Share Share
    Immutep Quarterly Activities Report Q1 FY24
    Immutep Quarterly Activities Report Q1 FY24

    https://www.globenewswire.com//news-release/2023/10/31/2770123/0/en/Immutep-Quarterly-Activities-Report-Q1-FY24.html

    GLOBENEWSWIRE
    31 Oct 2023
    Share Share
    Immutep receives ~A$1.13 million R&D Tax Incentive
    Immutep receives ~A$1.13 million R&D Tax Incentive

    https://www.globenewswire.com//news-release/2023/10/25/2766453/0/en/Immutep-receives-A-1-13-million-R-D-Tax-Incentive.html

    GLOBENEWSWIRE
    25 Oct 2023
    Share Share
    Immutep™s Efti Generates Excellent Overall Survival Benefit in NSCLC
    Immutep™s Efti Generates Excellent Overall Survival Benefit in NSCLC

    https://www.globenewswire.com//news-release/2023/10/23/2764683/0/en/Immutep-s-Efti-in-Combination-with-KEYTRUDA-Generates-Excellent-Overall-Survival-Benefit-in-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    23 Oct 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search